v3.25.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 18,130 $ 47,249
Research and development incentive receivable 739 704
Prepaid expenses and other current assets 292 86
Total current assets 19,161 48,039
Right of use assets, net 38 262
Research and development incentive receivable, net of current portion 59  
Deposits 784 823
Total assets 20,042 49,124
Current liabilities:    
Accounts payable 7,339 4,743
Accrued expenses 6,623 8,536
Income tax payable 324 531
Lease liability - current portion 39 266
Total current liabilities 14,325 14,076
Stockholders' equity:    
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively
Common stock, $0.001 par value; 240,000,000 shares authorized; 41,439,529 and 38,329,894 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 41 38
Additional paid-in capital 505,207 502,501
Accumulated other comprehensive loss (82) (120)
Accumulated deficit (499,449) (467,371)
Total stockholders' equity 5,717 35,048
Total liabilities and stockholders' equity $ 20,042 $ 49,124